CompletedPHASE1, PHASE2NCT00006357
STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma
Studying Alveolar rhabdomyosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Principal Investigator
- Jacob Verweij, MD, PhDDaniel Den Hoed Cancer Center at Erasmus Medical Center
- Intervention
- imatinib mesylate(drug)
- Enrollment
- 91 enrolled
- Eligibility
- 15 years · All sexes
- Timeline
- 2000
Study locations (16)
- Universitair Ziekenhuis Antwerpen, Edegem, Belgium
- U.Z. Gasthuisberg, Leuven, Belgium
- Aarhus Kommunehospital, Aarhus, Denmark
- Rigshospitalet, Copenhagen, Denmark
- Herlev Hospital - University Hospital of Copenhagen, Herlev, Denmark
- Centre Leon Berard, Lyon, France
- Institut Gustave Roussy, Villejuif, France
- Antoni van Leeuwenhoekhuis, Amsterdam, Netherlands
- Academisch Ziekenhuis Groningen, Groningen, Netherlands
- Leiden University Medical Center, Leiden, Netherlands
- University Medical Center Nijmegen, Nijmegen, Netherlands
- Rotterdam Cancer Institute, Rotterdam, Netherlands
- Royal Marsden NHS Trust, London, England, United Kingdom
- Christie Hospital N.H.S. Trust, Manchester, England, United Kingdom
- Nottingham City Hospital NHS Trust, Nottingham, England, United Kingdom
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00006357 on ClinicalTrials.govOther trials for Alveolar rhabdomyosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT05304585Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative RhabdomyosarcomaChildren's Oncology Group
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05071209Elimusertib for the Treatment of Relapsed or Refractory Solid TumorsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE3NCT04994132A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk RhabdomyosarcomaChildren's Oncology Group
- RECRUITINGPHASE3NCT06669013Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue SarcomasN.N. Petrov National Medical Research Center of Oncology
- ACTIVE NOT RECRUITINGNCT03296371Genetic Mutational Analysis of Saliva or Buccal Mucosa Samples From Patients With Embryonal or Alveolar RhabdomyosarcomaChildren's Oncology Group
- ACTIVE NOT RECRUITINGPHASE3NCT02567435Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk RhabdomyosarcomaNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE2NCT00077285Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk RhabdomyosarcomaMemorial Sloan Kettering Cancer Center